Fig. 1
AII consists of phenotypically novel T cells with cancer-eradicating capacity. A Degranulation analysis of AII upon 5 h culture alone, or with MDA-MB-231 cells, demonstrating degranulation of both NKAII and TAII cells. A representative of five experiments is shown. B-C Quantification of the degranulation of NKAII and TAII upon co-culture with MDA-MB-231 cells from five independent experiments presented as mean ± SD. D Cancer cell viability analysis (luminescence) following 24-h co-culturing with purified immune cell fractions. A representative of seven independent experiments is shown. Data is presented as mean ± SEM of triplicates. E Comparison of the LD50 from the data presented in D. F Comparison of percentage of CD4+, CD8+, and DN TAII cells in 10 AII preparations evaluated by flow cytometry. G Flow cytometry analysis of AII cells showing expression of CD45RO, but not CD45RA. H Phenotypic analysis of CD4+, CD8.+ and DN TAII cells with regard to CD62L, CD27, CD28 and CCR7 expression determined by flow cytometry I-J TCR clonotype analysis identifying thousands of TCR alpha and beta chains in each AII preparation. Preparations are dominated by 10–20 T cell clones. Statistical difference was determined using the paired t-test B-C and the Student’s t-test E. *0.05 > P ≥ 0.01, **0.01 > P ≥ 0.001